Introduction
Overduplication of the centrosome, the principal microtubule organizing centre of animal cells, allows the formation of multipolar mitotic spindles and may potentiate mis-segregation of chromosomes and the genome instability involved early in the development of tumours (Nigg, 2006; Fukasawa, 2007; Ganem et al., 2009) . Therefore, centrosome duplication occurs only once during the normal cell cycle (Doxsey et al., 2005; Bettencourt-Dias and Glover, 2007) . The mechanism of this restriction is not yet fully established, but current models invoke licensing, akin to that seen in DNA replication control (Tsou and Stearns, 2006) . Cyclindependent kinase (Cdk)2-cyclin E activation, which initiates in late G1 phase, is a key element that links DNA replication and centrosome duplication. Cdk2-cyclin E activity is required for centrosome re-duplication in frog embryos during S-phase arrest (Hinchcliffe et al., 1999; Lacey et al., 1999) . Centrosome overduplication in hydroxyurea (HU)-arrested CHO cells is reduced by expression of dominant-negative Cdk2 activity, whereas Cdk2-cyclin A is required to overcome a pRb mutant-induced inhibition of overduplication (Meraldi et al., 1999) . Furthermore, chemical inhibition of Cdk activity impedes centrosome overduplication in CHO cells, with such inhibition being overcome by Cdk2 overexpression (Matsumoto et al., 1999) . Conversely, Cdk2 null mice and DT40 cells are viable and able to duplicate their centrosomes (Berthet et al., 2003; Ortega et al., 2003; Duensing et al., 2006; Hochegger et al., 2007) . Moreover, in DT40 cells lacking Cdk2, Cdk1 has been shown to be required for centrosome duplication, suggesting redundant functions for Cdk1 and Cdk2 in this pathway (Hochegger et al., 2007) .
A complex and coordinated series of responses to DNA damage ensure that cells with genomic lesions do not continue to divide, but arrest their cell cycle and initiate DNA repair. Centrosome amplification is a frequent consequence of the DNA damage response (Sato et al., 2000; Dodson et al., 2004) , although the targets of this response that allow centrosome duplication while the chromosome cycle is arrested remain to be described. One of the key pathways directing this arrest is controlled by the Chk1 kinase. Upon activation by ATM/ATR, Chk1 phosphorylates and inhibits members of the Cdc25 phosphatase family from removing inhibitory phosphates from and activating Cdk-cyclin complexes (Sanchez et al., 1997; Zhao et al., 2002; Chen et al., 2003; Uto et al., 2004) . Chk1-dependent degradation of Cdc25 serves as an additional regulatory mechanism (Mailand et al., 2000 (Mailand et al., , 2002 Sampath et al., 2002; Shimuta et al., 2002) . In addition to controlling DNA damage responses through Chk1 activity on Cdc25, genotoxic stress leads to the activation of p53 and its target, the Cdk2 inhibitor, p21, thus inhibiting G1 phase Cdk2 activity (reviewed in (Tarapore and Fukasawa, 2002) ). In cells with mutations in p53, this inhibition no longer restrains centrosome duplication, so that p53-deficient cells frequently demonstrate numerically aberrant centrosomes (Fukasawa et al., 1996) . Overexpression of cyclin E exacerbates this phenotype in mouse (Mussman et al., 2000) and human (Kawamura et al., 2004) cells. However, DNA damageinduced centrosome amplification can occur independent of p53 mutation .
We have shown previously that Chk1 is required for DNA damage-induced centrosome amplification (Bourke et al., 2007) . Here, we use reverse genetics in chicken DT40 cells to explore how Chk1 signals to the Cdks that control centrosome duplication.
Results
To test Cdk2 as the principal effector of centrosome amplification in response to DNA damage, we first analysed the kinase activity of anti-Cdk2 immunoprecipitates from wild-type and Chk1 À/À DT40 cells after ionizing radiation (IR) treatment. Surprisingly, we found that irradiation of wild-type cells caused a rapid induction of Cdk2 kinase activity, as shown in Figures  1a and b . This increase in Cdk2 activity was not observed in Chk1-deficient cells, although the background level of Cdk2 activity in Chk1 À/À cells was elevated (238±83% of wild-type levels; N ¼ 3). The increase of activity was specific for Cdk2, as Cdk1 activity remained unchanged after IR treatment (Supplementary Figure 1 ). Furthermore, Cdk2 activity in Chk1 À/À cells was induced by treatment with the Cdk1 inhibitor, RO-3306, indicating that Cdk2 activity has not peaked in untreated Chk1-deficient cells (Figure 1c ). These findings indicate that Cdk2 activity is upregulated in response to DNA damage in a Chk1-dependent manner in DT40 cells.
We next tested whether Cdk2 upregulation occurred after DNA damage in human cells. As shown in Figure 1d , we found a striking increase in Cdk2 activity after irradiation of HeLa S3 cells. An increase in Cdk2 activity has also been observed in human ovarian cancer A2780 cells afer DNA damage induced by 1R,2R-diaminocyclohexane(trans-diacetato) (dichloro) platinum(IV) treatment (He et al., 2005) . However, in keeping with previously published work (Beamish et al., 1996; Cannell et al., 1998) , irradiation caused a marked decline in the Cdk2 activity seen in lymphoblastoid cells (Figure 1d) . A possible explanation for the variation in Cdk2 activation is the extent to which a given cell line is capable of p53-mediated cell-cycle arrest in G1. Both HeLa and DT40 cells lack functional p53 (Yamazoe et al., 2004) , whereas Epstein-Barr virus-transformed lymphoblastoid cells have a highly active p53 response (Cannell et al., 1998) . A model in which Cdk2 upregulation occurs during the Chk1-dependent G2 checkpoint in p53-deficient cells is consistent with our observations.
Given the role of Cdk2 in allowing centrosome overduplication during extended arrest in rodent cells (Duensing et al., 2006; Prosser et al., 2009) , the upregulation of Cdk2 after IR could be responsible for driving centrosome amplification. To test this idea, we monitored the number of centrosomes using immunofluorescence microscopy of g-tubulin, before and after IR in Cdk2 À/À DT40 cells (Hochegger et al., 2007) . We found that centrosome amplification after IR treatment occurred as efficiently as in wild-type cells (Figures 2a  and b) , demonstrating that Cdk2 is not required for IRinduced centrosome amplification. To examine the role of Cdk1, we used Cdk1 À/À cells that express only a chemically inhibitable (analogue-sensitive, AS) mutant form of Cdk1 (Hochegger et al., 2007) . For simplicity, we refer to the Cdk1 À/À Cdk1 AS cells as Cdk1 OFF after addition of the inhibitor. In these cells inhibition of Cdk1 causes a prolonged G2 arrest during which centrosomes continue to duplicate (Hochegger et al., 2007) . Consistent with this observation, we found that Cdk1 OFF cells displayed increased centrosome numbers, which were somewhat diminished after IR. Conversely, IR-induced centrosome amplification was abolished in cells lacking both Cdk1 and Cdk2 activity (Figures 2a and b) . These data indicate that either Cdk1 or Cdk2 is sufficient, but that neither protein is individually required for aberrant centrosome duplication.
Next, we explored the interplay between Cdk1 and Cdk2 by monitoring their respective activities in mutants of the other gene. As shown in Figure 2c , IR-induced Cdk1 activity was higher in Cdk2-deficient cells than in wild-type, whereas Cdk1 deficiency resulted in a large increase in Cdk2 activity that was not further increased by irradiation. These results show that the upregulation of either Cdk1 or Cdk2 activity allows centrosome amplification in the absence of the other kinase. Furthermore, these data demonstrate that Cdk1 and Cdk2 activities have an impact on one another, as has also been noted in experiments examining Cdk2 À/À mice (Satyanarayana et al., 2008) .
Our next experiment examined the requirement for Cdk2 in centrosome overduplication during extended S-phase arrest in DT40 cells. Cdk2 is required for centrosome overduplication in HU-and HPV-16 E7 oncogene-induced centrosome overduplication in mouse cells (Duensing et al., 2006; Prosser et al., 2009) . Conversely, we found that HU treatment caused centrosome overduplication in the absence of either Cdk1 or Cdk2 activity, but not in cells wherein neither Cdk was active ( Figure 2d ). That HU treatment still allows a high level of centrosome amplification in Cdk1
OFF cells may reflect a limited number of cells overcoming an HU arrest and re-duplicating their centrosomes during an extended G2 arrest imposed by Cdk1 deficiency (Supplementary Figure 2) . Thus, Cdk2 is not essential for HU-induced centrosome amplification in DT40 cells, indicating that there are different controls on the substitution of Cdk2 activities by Cdk1 in chicken and mouse cells. We also examined whether Chk1 was required for HU-induced centrosome amplification. Chk1 deficiency did not block HU-induced centrosome overduplication (Figure 2d ), indicating that despite its localization to the centrosome (Kramer et al., 2004) , Chk1 is not involved in centrosome duplication in S-phase arrested cells. Therefore, Chk1 is specifically involved in centrosome amplification in response to DNA damage response, suggesting that the mechanisms underlying HU-and IR-induced centrosome amplification are not the same. This is also consistent with the maturity of the centrioles differing after overamplification induced by either treatment (Saladino et al., 2009) .
We next tested whether the observed Cdk2 induction in response to IR resulted from upregulation of its regulatory partners, cyclin A or cyclin E. Both cyclin A and E are involved in centrosome duplication (Hinchcliffe et al., 1999; Lacey et al., 1999; Meraldi et al., 1999) . Analysis of cyclin E-deficient fibroblasts has indicated that the requirement for either cyclin in allowing centrosome duplication changes during the cell cycle, with cyclin E being primarily involved in licensing the centrosome for duplication during G1 early S-phase (Wong and Stearns, 2003) and cyclin A being more involved in damage-induced amplification, which is believed to occur during G2 phase (Dodson et al., 2004; Hanashiro et al., 2008) . Moreover, cyclin E overexpression in p53-deficient mouse cells induced centrosome amplification, but little impact was seen in wild-type rat or mouse fibroblasts (Spruck et al., 1999; Mussman et al., 2000) . On the other hand, centrosome overduplication in HU-arrested human cells is driven by cyclin A, but not cyclin E, overexpression (Meraldi et al., 1999; Balczon, 2001) . We observed no increase of cyclin A or cyclin E protein after the irradiation of wildtype or Chk1 À/À cells (Figures 3a and b) . Northern blot analysis showed no transcriptional upregulation of either gene (data not shown). However, Chk1-deficient cells constitutively expressed higher levels of cyclin A and lower levels of cyclin E than wild-type cells (Figures 3a and b) , which may contribute to the increased Cdk2 activity that we observed in these cells ( Figure 1a ). These observations prompted us to examine the impact of overexpressing cyclin A or cyclin E on DNA damage-induced centrosome amplification in Chk1 null cells. As shown in Figures 3c and d , overexpression of cyclin E, but not cyclin A, partially restored centrosome amplication after irradiation of Chk1 À/À cells. However, although DT40 cells lack functional p53, only a minor level of centrosome amplification is caused by cyclin overexpression in the absence of DNA damage (Figure 3c ). These data indicate that elevated cyclin E levels alone are not sufficient for centrosome overduplication in DT40 cells, but that they can partially compensate for the inability of Chk1-deficient cells to upregulate Cdk2 activity as a DNA damage response.
Our observation that Cdk2 is activated in a Chk1-dependent manner in response to IR, whereas cyclin E and A levels are not affected, suggests that Chk1 positively controls Cdk2 independently of cyclin synthesis. Regulation of Cdk2 activity includes an activating phosphorylation on Thr-160 and an inhibitory phosphorylation on Tyr-15. As Cdk1 and Cdk2 levels remain constant in wild-type and Chk1-deficient cells after irradiation (Figure 4a ), we hypothesized that the radiation-induced increase in Cdk2 activity could arise from altered phosphorylation. Immunoblot analysis revealed that Thr-160 phosphorylation was indeed significantly elevated after irradiation of wild-type, but not of Chk À/À cells (Figure 4a ). To test the requirements for the phosphorylation sites in Cdk2, we transfected Cdk2
OFF cells with a Cdk2 transgene and then counted the centrosomes. Exogenous Cdk2 expression caused centrosome amplification and restored DNA damage-induced centrosome amplification to wild-type levels in Cdk1-deficient Cdk2 null cells (Figures 4b and c;  Supplementary Figure 3) . Mutation of the activating Thr-160 site to Ala abolished centrosome amplification, whereas alteration of Thr-160 to Glu or the inhibitory Tyr-15 to Phe caused the same levels of centrosome amplification as were seen with the wild-type protein (Figure 4b ). These results indicate that Thr-160 phosphorylation is required to allow Cdk2-mediated centrosome amplification, but that such an amplification is not limited by inhibitory Tyr-15 phosphorylation. We could not detect Cdk2 expression of a Thr-160 to Glu/Tyr-15 to Phe double mutant in three separate experiments (data not shown), suggesting that this protein is unstable or toxic to cells. Likewise, Cdk2 overexpression in Chk1 À/À cells was sufficient to cause centrosome amplification, with no additional increase in centrosome numbers after irradiation (Figures 4c and d) . The Thr-160 phosphorylation site was necessary for Cdk2-induced centrosome amplification, with no additional centrosome aberrations apparent upon mutation of the inhibitory Tyr-15 site. We then tested the in vitro kinase activity of the Cdk2 mutants used in these rescue experiments. As shown in Figure 4e , Cdk2 Y15F had the highest Cdk2 kinase activity, consistent with no inhibitory signal being mediated by Tyr-15 phosphor- Figure 2c . Wild-type, Chk1
AS DT40 cells were cultured and irradiated as previously described (Zachos et al., 2003; Bourke et al., 2007; Hochegger et al., 2007) . Cells were lysed in lysis buffer (50 mM HEPES pH 7.5, 150 mM NaCl, 0.1% Tween-20, 1 mM EDTA, 10% glycerol, 1 mM DTT, 1 mM PMSF, 1 mM NaVO 4 , 1 mM aprotinin and 1 mM pepstatin) for 1 h at 4 1C. Immunoprecipitation was carried out with antibodies to Cdk2 (M2; sc-163, Santa Cruz, Heidelberg, Germany) or Cdk1 (sc-54; Santa Cruz). Protein G beads were used to isolate the antibody-protein complexes which were washed twice with lysis buffer, then twice in kinase buffer (Cdk1: 10 mM HEPES pH 7.5, 25 mM KCl, 10 mM NaCl, 1 mM MgCl 2 0.1 M EDTA, 1 mM DTT, 1 mM PMSF, 1 mM NaVO 4 , 1 mM aprotinin, 1 mM pepstatin; Cdk2: 50 mM HEPES pH 7.5, 50 mM NaCl, 10 mM MgCl 2 , 10 mM MnCl 2 , 1 mM DTT, 1 mM PMSF, 1 mM NaVO 4 , 1 mM aprotinin and 1 mM pepstatin) and resuspended in 40 ml of kinase buffer containing 100 mM ATP, 1 mg Histone H1 (Sigma, Dublin, Ireland), 10 mCi DNA damage activates Cdk2 in p53-deficient cells E Bourke et al ylation, followed by wild-type Cdk2, then T160E, which had a notably lower activity in vitro, despite its capacity to rescue centrosome amplification. Cdk2 T160A had only background levels of kinase activity, consistent with the activating phosphorylation of Thr-160 being a prerequisite for in vitro Cdk2 activity. 
Discussion
In this study we have demonstrated a Chk1-dependent increase in Cdk2 activity concomitant with an increase in Thr-160 phosphorylation in response to IR. The Chk1 requirement for this pathway can be bypassed by exogenous overexpression of wild-type, but not T160A Cdk2, suggesting that this activation step is the essential function of Chk1 in DNA damage induced centrosome amplification. It is interesting to note that this increase in activity was specific to Cdk2 in wild-type cells, but occurred in Cdk1 when Cdk2 was deleted. Accordingly, we conclude that Cdk2 is not required for centrosome amplification after damage and can be compensated for by Cdk1. However, if both Cdk1 and 2 are inactivated, centrosome amplification is abolished. Thus, Cdk2 is sufficient, but not essential to control centrosome numbers in response to IR. Taken together, a model emerges from these results suggesting that a global increase of Cdk2 activity through DNA damageinduced Thr-160 phosphorylation or its overexpression can drive centrosome amplification. Our observation that cyclin E, but not cyclin A, overexpression partially restores amplification in Chk1 null cells suggests that this signalling pathway primarily affects the pool of Figure 2 Requirement of cyclin-dependent kinase (Cdk)1 or Cdk2 for centrosome amplification in DT40 cells. (a) Immunofluorescence micrograph showing radiation-induced centrosome amplification in Cdk-deficient DT40 cells. Cells of the indicated genotype were fixed and stained 12 h after 10 Gy g-irradiation for centrin (green), g-tubulin (red) and counterstained with 1R,2R-diaminocyclohexane(trans-diacetato) (dichloro) platinum(IV) (DAPI) (blue). Scale bar, 10 mm. Cells were fixed and stained for g-tubulin as previously described (Bourke et al., 2007) , also using polyclonal anti-centrin (#628802, Biolegend, Uithoorn, the Netherlands). Microscopy and centrosome analyses were as previously described (Bourke et al., 2007) . ( À/À cells transfected with the indicated expression vectors or empty control. Chicken Cdk2 and cyclin E were cloned by PCR from DT40 cDNA into pCMV-3Tag-2 (Stratagene, La Jolla, CA, USA). pCMV-neo/mycCyclin A was a gift from Prof. Erich Nigg, MPI Martinsreid, Germany. Cells were transiently transfected with 15 mg of endotoxin-free plasmid DNA using nucleofection (Amaxa, Cologne, Germany). Cells were incubated for 24 h, then treated with 10 Gy g-irradiation and incubated for a further 12 h before analysis. (d) Immunoblot analysis of transfections analysed in (c).
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Cdk2 that is in a complex with cyclin E. This fits well with observations that cyclin E primarily binds Cdk2, but can switch to Cdk1 after Cdk2 deletion (Aleem et al., 2005) .
A recent study demonstrated that in both wild-type murine fibroblasts and in cells with a stabilizing point mutation in Cdc25A, total cellular Cdk2 activity decreased shortly after IR, with a concomitant increase in inhibitory phosphorylation of Cdk2 (Shreeram et al., 2008) . However, centrosome amplification still occurred in the Cdc25A mutant cells after IR and no radiationinduced increase in inhibitory Cdk2 phosphorylation was seen at centrosomes. Likewise, we find that the phosphorylation of Cdk2 Tyr-15 has little impact on centrosome amplification, which seems to depend on a new regulatory pathway involving Thr-160. Consistent with our data that either Cdk1 or Cdk2 control centrosomal responses to DNA damage, DNA damage-induced centrosome amplification was suppressed by chemical inhibition of Cdk activity (Shreeram et al., 2008) . Cdk2 has been described as being involved in DNA repair (Muller-Tidow et al., 2004) and in apoptotic responses (reviewed in (Berthet and Kaldis, 2007) ). Our discovery that Cdk2 activity increases in response to genotoxic stress through Chk1-dependent phosphorylation to allow centrosome amplification, provides a further mechanistic link between the DNA damage checkpoint and the centrosome duplication apparatus.
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